MedTrace Logo

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

NCT03197467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-04

Study results available
· View outcomes & findings →

Summary

NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Pembrolizumab

Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles

Sponsors & Collaborators

Principal Investigators

  • Martin E. Eichhorn, PD Dr. med. · University Hospital Heidelberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-18
Primary Completion
2021-10-30
Completion
2023-05-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03197467 on ClinicalTrials.gov